117 related articles for article (PubMed ID: 35132321)
1. Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma.
Wen CY; Tsui KH; Chang CH; Chiu YH; Lin SA; Chu CY; Li CJ
J Oncol; 2022; 2022():9854788. PubMed ID: 35132321
[TBL] [Abstract][Full Text] [Related]
2. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
[TBL] [Abstract][Full Text] [Related]
3. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
4. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer.
Ge H; Yan Y; Yan M; Guo L; Mao K
Med Sci Monit; 2020 Jun; 26():e923208. PubMed ID: 32562536
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease as a Risk Factor for Prostate Adenocarcinoma: A Molecular Point of View.
Liu T; Yang Z; Liu S; Wei J
Gerontology; 2023; 69(8):986-1001. PubMed ID: 36921580
[TBL] [Abstract][Full Text] [Related]
6. Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
Liu L; Li Y; Tang S; Yang B; Zhang Q; Xiao R; Hou X; Liu C; Ma L
Int J Biol Markers; 2023 Jun; 38(2):114-123. PubMed ID: 37192745
[TBL] [Abstract][Full Text] [Related]
7. Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma.
Hu QY; Liu J; Zhang XK; Yang WT; Tao YT; Chen C; Qian YH; Tang JS; Yao XS; Xu YH; Wang JH
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770929
[TBL] [Abstract][Full Text] [Related]
8. Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer.
He T; Zhang Y; Li X; Liu C; Zhu G; Yin X; Zhang Z; Zhao K; Wang Z; Zhao P; Wang K
World J Surg Oncol; 2022 Jun; 20(1):174. PubMed ID: 35650630
[TBL] [Abstract][Full Text] [Related]
9. Identification of FAM107A as a potential biomarker and therapeutic target for prostate carcinoma.
Ma YF; Li GD; Sun X; Li XX; Gao Y; Gao C; Cao KX; Yang GW; Yu MW; Wang XM
Am J Transl Res; 2021; 13(9):10163-10177. PubMed ID: 34650688
[TBL] [Abstract][Full Text] [Related]
10. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
11. High expression of KNL1 in prostate adenocarcinoma is associated with poor prognosis and immune infiltration.
Zhang Y; Ji Q; Wang J; Dong Y; Pang M; Fu S; Wei Y; Zhu Q
Front Genet; 2022; 13():1100787. PubMed ID: 36685823
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD).
Xin S; Sun X; Jin L; Li W; Liu X; Zhou L; Ye L
Front Genet; 2022; 13():877278. PubMed ID: 35706452
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
14. Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma.
Qiao S; Zhang W; Su Y; Jiang Y
Front Oncol; 2022; 12():1037535. PubMed ID: 36591519
[TBL] [Abstract][Full Text] [Related]
15. Neuropilin1 Expression Acts as a Prognostic Marker in Stomach Adenocarcinoma by Predicting the Infiltration of Treg Cells and M2 Macrophages.
Kang JY; Gil M; Kim KE
J Clin Med; 2020 May; 9(5):. PubMed ID: 32408477
[TBL] [Abstract][Full Text] [Related]
16. Screening a novel six critical gene-based system of diagnostic and prognostic biomarkers in prostate adenocarcinoma patients with different clinical variables.
Munir H; Ahmad F; Ullah S; Almutairi SM; Asghar S; Siddique T; Abdel-Maksoud MA; Rasheed RA; Elkhamisy FAA; Aufy M; Yaz H
Am J Transl Res; 2022; 14(6):3658-3682. PubMed ID: 35836886
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Profiles Reveal a 12-Signature Metabolic Prediction Model and a Novel Role of Myo-Inositol Oxygenase in the Progression of Prostate Cancer.
Liu W; Xiang J; Wu X; Wei S; Huang H; Xiao Y; Zhai B; Wang T
Front Oncol; 2022; 12():899861. PubMed ID: 35669435
[TBL] [Abstract][Full Text] [Related]
18. Zinc finger C3H1 domain-containing protein (ZFC3H1) evaluates the prognosis and treatment of prostate adenocarcinoma (PRAD): A study based on TCGA data.
Huang H; Xu H; Li P; Ye X; Chen W; Chen W; Huang X
Bioengineered; 2021 Dec; 12(1):5504-5515. PubMed ID: 34514952
[TBL] [Abstract][Full Text] [Related]
19. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.
Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y
Front Genet; 2022; 13():886983. PubMed ID: 35547260
[No Abstract] [Full Text] [Related]
20. Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma.
Lu G; Shi W; Zhang Y
Front Genet; 2021; 12():721021. PubMed ID: 34925439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
